ArsenalBio scores $85 mln Series A

South San Francisco-based ArsenalBio, a developer of a cell therapy company, has secured $85 million in Series A financing. The investors included Westlake Village BioPartners, the Parker Institute for Cancer Immunotherapy, Kleiner Perkins, the University of California, San Francisco Foundation Investment Company, Euclidean Capital and Osage Venture Partners.

North AmericaUSBriefs